Novo Nordisk transfers Parkinson's cell therapy to Zuckerberg-backed Cellular Intelligence

Cellular Intelligence Acquires Clinical-Stage Cell Therapy Program

Cellular Intelligence announced Monday it has secured global rights to STEM-PD, Novo Nordisk's experimental Parkinson's disease stem-cell therapy that was discontinued last October during the Danish drugmaker's broader restructuring 1

1

. The AI-backed startup, which has raised more than $60 million from investors including Khosla Ventures and the Chan Zuckerberg Initiative founded by Mark Zuckerberg and Priscilla Chan, now controls a clinical-stage cell therapy program already in a first-in-human Phase 1/2 clinical trial 2

2

.

Financial terms were not disclosed, but Novo Nordisk will take an equity stake in Cellular Intelligence and remains eligible for future milestone payments and royalties 3

3

. The deal closes immediately and represents what CEO Micha Breakstone called "a defining moment" for the Boston-based company.

STEM-PD Targets Dopamine-Producing Nerve Cells

STEM-PD is an allogeneic, stem-cell-derived treatment designed to replace dopamine-producing nerve cells lost in Parkinson's disease, a progressive brain disorder leading to tremors, stiffness and slow movement 3

3

. The therapy uses stem cells from donors that are transformed into early-stage brain cells meant to become dopamine-producing neurons 2

2

.

The treatment has received FDA Fast Track designation, a status meant to expedite the review of therapies for serious conditions with unmet medical needs 4

4

. Parkinson's affects between 10 million and 12 million people worldwide, and treatments that replace lost dopamine-producing cells have been pursued by multiple research groups for decades 1

1

4

4

.

AI Platform to Accelerate Development and Manufacturing

Cellular Intelligence intends to apply its proprietary AI platform to accelerate the program, scale manufacturing and bring down production costs 1

1

. The company's AI foundation model is trained on millions of cellular perturbation conditions and aims to compress traditional cell-therapy timelines while reducing production costs, a key barrier to commercializing complex regenerative-medicine products 4

4

.

"We are building an AI-native, fully integrated therapeutics company. The same platform that learns how cells respond to signals can help design better protocols, improve manufacturability, optimize functional dose, and deepen our understanding of how development decisions connect to clinical outcomes," Breakstone said 2

2

. He added that "optimizing and scaling complex cell therapy programs to reach patients globally is exactly the challenge our AI-native platform was built to solve" 4

4

.

Bloomberg reports that Cellular Intelligence plans to start a mid-stage trial of the therapy early next year, with data from the trials used to further train the AI model 2

2

. Breakstone characterized the deal as marking "the beginning of an AI-native era for cell replacement therapy, one where biology is no longer destiny, but design" 3

3

.

Novo Nordisk Refocuses on Obesity and Diabetes Franchises

For Novo Nordisk, the deal closes out one of the loose ends from last October's restructuring, which prioritized the company's obesity and diabetes franchises after demand for Wegovy and Ozempic continued to outpace supply 1

1

. The cell-therapy unit was an early-stage research operation rather than a commercial line, and its discontinuation freed engineering and manufacturing capacity for GLP-1 production 1

1

.

Last week Novo reported that Wegovy held 65% of new US prescriptions and that obesity-care sales rose 22% on a constant-currency basis 1

1

. The cuts came amid restructuring at the company aimed at cutting costs and refocusing research efforts as part of Chief Executive Mike Doustdar's plan to regain ground lost to rival Eli Lilly in the weight-loss market 4

4

5

5

.

"We are convinced that Cellular Intelligence has the capabilities needed to move it forward," said Jacob Petersen, Novo Nordisk's senior vice president of global research. "The convergence of developmental biology and genomics, and the possibility of combining this with AI on a single platform, provide an exciting opportunity in medicine in general, and for the cell therapy field in particular" 4

4

.

Proving Ground for AI-Driven Cell Therapy

For Cellular Intelligence, the deal provides a clinical-stage asset to anchor its AI-platform pitch and a chance to prove whether its technology can actually help accelerate the development of complicated treatments like STEM-PD 2

2

. STEM-PD is well-characterized, with Novo Nordisk's prior investment taking it through the preclinical and early-clinical stages 1

1

.

To lead clinical advancement, Cellular Intelligence has appointed neurologist Nuno Mendonça as chief medical officer. Mendonça has previously held senior roles at Bial, AbbVie, and Novartis Gene Therapies, overseeing neuroscience and rare-disease programs across North America and Europe 4

4

. The startup's case to investors now combines an in-development therapy with the cost-and-speed claims its AI platform is built around, positioning it to demonstrate whether a commercially viable treatment for Parkinson's disease can be achieved on a timeline conventional cell-therapy programmes have not matched 1

1

.